Conferences
20–23 February 2012, Shanghai, China
Antibodies Asia 2012
Antibody-based therapeutics currently enjoys exceptional success in the global biologic drug market. Achieving a total sale of nearly US$35 billion and holding six spots out of the top 20 best-selling pharmaceutical products in 2008, monoclonal antibodies (mAb) sales are predicted to grow exponentially to reach US$50 billion in 2013.
Rising research interest is further compelled by the large market potential that these substances may offer. Its ability to treat a wide range of complex diseases relating to oncology, inflammation and autoimmune diseases make the development of novel, proprietary antibodies top on every biopharmaceutical companies’ list. In addition, biosimilar antibodies on its own also represent a huge, multibillion-dollar opportunity for generic manufactures in the United States, Europe and Asia.
With the latest hype in biosimilar antibodies and promising success in developing bi-specific antibodies using new platform, the advancement in the field of therapeutic antibodies unravel more commercial opportunities and renewed optimism for the industry, making it an even more lucrative and dynamic market for investors.
Join us at IBC’s 4 th Annual Antibody Asia conference to learn about the latest antibody research and development, industry trends and updates and ways to expedite your antibody pipeline into revenue-generating biologics. Held from 20 th to 22 nd February in Shanghai, we promise to put together the most beneficial and multi-faceted agenda, delivered by internationally renowned speakers, specially catered to match your interest.
